Only 313 patients completed p2b/3 which likely means fewer than 300 patients participated in OLE. The option of using OLE as a confirmatory trial is probably not realistic. In addition, OLE didn’t change the titrition protocol. We might be lucky to get half of the original 500 patients completing the OLE. Not ideal. Perhaps this is where
could be complementary to the currently approved anti-beta amyloid monoclonal antibody drugs
Market Data 
Markets 
AI
